Ark Pacific SpecialOpportunities Fund
Ark Pacific Special Opportunities Fund focuses on identifying opportunities and investing in equities across the Asia-Pacific region. The fund holds shares in companies such as Comtec Solar Systems Group Ltd, a Hong Kong-listed company, and others. The market value of its holdings in Comtec Solar alone exceeds 7 million USD.
Sinoway Investment Corporation
Sinoway Investment Corporation was founded and initiated by Mr. Dao eng He in 1995. After Beijing Geyuan Investment Consulting Co., Ltd. was established in 2001, it became a subsidiary company controlled by GeYuan.
Sinoway Investment Corporation is one of the earlier professional investment companies established in China. It has a strong domestic focus and a deep understanding of the Chinese investment landscape. Its business scope includes industrial investment, equity investment, and debt investment. Main operations encompass mergers and acquisitions (M&A), restructuring, asset management, investment management, and fund management.
The company’s investment sectors cover commercial retail, real estate, hotel operations, tourism development, chemicals, biopharmaceuticals, and more. Its investment regions primarily include Beijing and its surrounding areas, the Yangtze River Delta region near Shanghai, Southwest China, and other key areas. The total assets of its investments and controlled entities exceed 6 billion RMB.
KunMing Sinobright Department Store
In 2001, Beijing Geyuan Investment Consulting Co., Ltd., through its controlling subsidiary Sinoway Investment Corporation, invested in KunMing Sinobright Department Store Co., Ltd. (stock code: 000560), Yunnan’s largest commercial enterprise listed on the Shenzhen Stock Exchange, with total assets exceeding 1.3 billion RMB. At that time, the company was deeply mired in massive debt, insolvent, and on the verge of bankruptcy. After Sinoway Investment Corporation took control, it promoted debt restructuring, institutional reforms, and other self-rescue measures. The company cut hundreds of cash-burning projects that were draining its resources, redirected its limited funds and talent to focus on its core department store and hotel businesses, and gradually turned losses into profits. Subsequently, Mr. Dao Feng He once again drove asset mergers and acquisitions as well as restructuring for KunMing Sinobright Department Store Co., Ltd., which significantly improved the company’s cash position and led to a substantial increase in its market capitalization.
Yunnan Lvdadi Biotechnology
Yunnan Lvdadi Biotechnology Co., Ltd. a Chinese public company listed in 2007, is a leading ecological and landscaping enterprise headquartered in Kunming. The company specializes in seedling cultivation, landscaping engineering, and ecological restoration, possessing a complete industrial chain from research and development to project implementation. It has established six major ornamental seedling and potted plant cultivation bases in Yunnan Province, forming a multi-level and diversified large-scale production and planting system.
Kunming Sinoway Natural Pharmaceuticals
Kunming Sinoway Natural Pharmaceuticals Co., Ltd. was founded in 1998 and is a high-tech pharmaceutical enterprise integrating the research and development, production, and sales of chemical preparations, traditional Chinese medicines, and biopharmaceuticals. It was invested in and acquired by Sinoway Investment Corporation in 1998 and has gradually developed into a modern pharmaceutical company specializing in macromolecular biologics and chemical drugs.
Sinoway Pharmaceutical’s core therapeutic areas include cardiovascular and cerebrovascular diseases, digestive system disorders and wound repair, anti-hepatitis B antiviral treatments, orthopedics and trauma, as well as topical medications. Its representative products include Kangfuxin Ye (Rehabilitation New Liquid, a nationally protected traditional Chinese medicine), Ganlong Capsules (a national Class II new drug), Xinluoping (an innovative antihypertensive drug), Yimaikang Tablets, Xibi Yi (a patented nasal wash product), Ningxinbao (Cordyceps sinensis refined capsules), and others.
With its core competitiveness centered on distinctive traditional Chinese medicine combined with innovative R&D, Sinoway Pharmaceutical is developing toward large-scale and innovation-driven growth, aiming to become a representative biopharmaceutical enterprise in Yunnan.
Shanghai Fanghe Investment
Shanghai Fanghe Investment Center is a professional fund management firm specializing in investment management and asset management, founded in 2015. The Company’s core business focuses on equity investments in growth-stage projects within emerging industries, with particular emphasis on the internet, healthcare, and consumption upgrade sectors. It has established a broad investment network in areas such as technology promotion, pharmaceutical manufacturing, and consumer services, consistently identifying the value of high-growth enterprises.
By leveraging the deep industry insights of its professional investment team, the company has constructed a diversified investment portfolio covering multiple sectors, including technology promotion, pharmaceutical manufacturing, software services, and consumer services. As an active capital platform, it provides continuous support to high-growth enterprises through disciplined and rigorous investment strategies, demonstrating strong resource integration capabilities and superior market adaptability in the equity investment field.
Key portfolio companies include: Novogene Co., Ltd. (listed on the Shanghai Stock Exchange in 2021) and Wuhan Abogen Biosciences Co., Ltd. (IPO).
Shanghai Purun Phase IV
Shanghai Purun Phase IV Equity Investment Partnership Enterprise, founded in 2016, is a professional investment institution specializing in growth-stage equity investment and strategic integration.
The Company’s core business encompasses equity investment, investment management, asset management, and venture capital, with a primary focus on leading entrepreneurial companies in advanced manufacturing, modern services, healthcare, and consumer sectors. By managing both RMB and USD investment funds, the Company provides professional capital operation services to its investors.
In its equity investment practice, the company relies on in-depth industry research and strong resource integration capabilities to implement a value-driven investment strategy supported by a systematic post-investment management system. Through the operation of a professional team, the Company has accumulated extensive investment experience in relevant fields and established a robust risk control mechanism.
Key portfolio companies include: Zhejiang Huayuan Automotive Technology Co., Ltd. (listed on the Shenzhen Stock Exchange in 2025), Daosheng Advanced Materials Technology (Shanghai) Co., Ltd. (listed on the Shanghai Stock Exchange in 2025), and others.
Shanghai Fengrui Venture
Shanghai Fengrui Venture Investment Center (Limited Partnership) was founded in 2015, and is a professional institution specializing in early-stage venture capital investment. It is dedicated to identifying and supporting the development of startups with strong innovation potential.
With early-stage investment as its core driver, the Company simultaneously deploys capital in growth-stage and mid-to-late-stage projects. Its investment strategy centers on three strategic pillars: consumer & TMT, hard technology, and biomedicine. Through in-depth resource integration, it has systematically invested in hundreds of innovative enterprises, building a diversified investment portfolio in cutting-edge fields such as artificial intelligence, intelligent manufacturing, and biotechnology. Its portfolio companies span multiple high-growth sectors, demonstrating exceptional industry insight and resource integration capabilities.
As an active capital platform, Fengrui leverages its acute sensitivity to emerging trends to provide invested companies with strategic guidance and extensive resource network support, thereby driving sustained value enhancement and long-term sustainable development.
Key portfolio companies include: Qingdao Zhiteng Technology Co., Ltd. (IPO), Nanjing Xinshijie Microelectronics Technology Co., Ltd. (IPO), and others.
Tianjin Shangshi VentureInvestment Fund
Tianjin Shangshi Venture Investment Fund is a professional investment fund established within China’s private equity and venture capital ecosystem, managed by Beijing Shangshi Investment Management Co., Ltd. Founded in 2014, Shangshi Capital manages multiple RMB and USD-denominated funds, with total assets under management exceeding 1.5 billion RMB. The fund primarily focuses on early and growth-stage investments (Seed to Series B), with key sectors including digital healthcare and life sciences, consumer upgrade, Internet of Things (IoT), enterprise services, and technological innovation.
To date, Shangshi Capital has invested in more than 60 companies across sectors such as medical technology, smart hardware, and consumer technology, and has established deep collaborations with numerous domestic and international institutions.
GeYuan Group
